Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
22.09. | Trinity Capital provides $45M in growth capital to Rapid Micro Biosystems | 15 | Seeking Alpha | ||
13.08. | Stifel bestätigt Kaufempfehlung für Rapid Micro Biosystems und hält an Kursziel von 8 US-Dollar fest | 17 | Investing.com Deutsch | ||
13.08. | Stifel reiterates Buy rating on Rapid Micro Biosystems stock, maintains $8 target | 2 | Investing.com | ||
12.08. | Rapid Micro Biosystems reaffirms $32M revenue guidance for 2025 as recurring revenue climbs 15% | 1 | Seeking Alpha | ||
12.08. | Rapid Micro Biosystems secures $45 million term loan facility | 2 | Investing.com | ||
12.08. | Rapid Micro Biosystems GAAP EPS of -$0.27, revenue of $7.3M | 1 | Seeking Alpha | ||
RAPID MICRO BIOSYSTEMS Aktie jetzt für 0€ handeln | |||||
12.08. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Reports Second Quarter 2025 Financial Results | 611 | GlobeNewswire (Europe) | Reports second quarter 2025 total revenue of $7.3 million, representing 10% growth compared to the second quarter of 2024. Second quarter 2025 recurring revenue increased 15% compared to the second... ► Artikel lesen | |
12.08. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Enters into Five-Year, $45 Million Term Loan Facility with Trinity Capital Inc. | 640 | GlobeNewswire (Europe) | $20 million drawn down at closing, with access to up to an additional $25 million Strengthens Company's financial position and reinforces ability to achieve positive cash flow LEXINGTON, Mass.,... ► Artikel lesen | |
12.08. | RAPID MICRO BIOSYSTEMS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
11.08. | A Look Ahead: Rapid Micro Biosystems' Earnings Forecast | 2 | Benzinga.com | ||
31.07. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems to Announce Second Quarter 2025 Financial Results on August 12, 2025 | 2 | GlobeNewswire (USA) | ||
28.07. | Lake Street initiates Rapid Micro Biosystems stock with Buy rating on MQC growth | 6 | Investing.com | ||
28.07. | Automatisierte Qualitätskontrolle als Wachstumstreiber: Lake Street stuft Rapid Micro Biosystems mit "Buy" ein | 2 | Investing.com Deutsch | ||
17.06. | RAPID MICRO BIOSYSTEMS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
13.06. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 215 | GlobeNewswire (Europe) | LEXINGTON, Mass., June 13, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation... ► Artikel lesen | |
27.05. | Rapid Micro Biosystems appoints new board member | 1 | Investing.com | ||
27.05. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Announces Appointment of Dr. Dafni Bika to Board of Directors | 1 | GlobeNewswire (USA) | ||
23.05. | RAPID MICRO BIOSYSTEMS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
09.05. | RAPID MICRO BIOSYSTEMS, INC. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
09.05. | Rapid Micro Biosystems reports Q1 results | 2 | Seeking Alpha |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 40,530 | +0,15 % | Sysmex, QIAGEN Announce Exclusive Distribution Partnership For Diagnostic Products In Japan | TOKYO (dpa-AFX) - Sysmex Corporation (SSMXY.PK) and QIAGEN K.K., the Japanese subsidiary of QIAGEN N.V., announced on Wednesday that they have entered into a partnership for clinical diagnostic... ► Artikel lesen | |
ARCUTIS BIOTHERAPEUTICS | 20,050 | -3,19 % | Arcutis Biotherapeutics, Inc.: FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 | ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well toleratedOnce-daily, steroid-free cream can be used anywhere... ► Artikel lesen | |
EVOTEC | 6,724 | +0,39 % | Evotec Aktie: Strohfeuer oder klappt es diesmal? | Die Evotec Aktie zeigt Stärke - aber diesmal auch für eine längere Zeit? Seit dem 26. September hat sich die TecDAX-notierte Biotech-Aktie von 5,882 Euro um mehr als einen Euro verteuert. Am gestrigen... ► Artikel lesen | |
89BIO | 14,800 | -0,34 % | Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB). The offer includes... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,305 | -10,24 % | RECURSION PHARMACEUTICALS INC zündet den Turbo jetzt! | ||
BEAM THERAPEUTICS | 26,340 | -5,49 % | Jefferies stuft Beam Therapeutics auf "Buy": Kommende Katalysatoren im Fokus | ||
MOONLAKE IMMUNOTHERAPEUTICS | 10,290 | +9,70 % | Oppenheimer senkt Kursziel für Moonlake Immunotherapeutics nach durchwachsenen Studienergebnissen | ||
LENZ THERAPEUTICS | 38,740 | -16,24 % | Piper Sandler raises LENZ Therapeutics stock price target to $67 on VIZZ launch | ||
MINERALYS THERAPEUTICS | 42,170 | +7,06 % | Mineralys Therapeutics: Aktie erreicht Rekordhoch von 41,11 USD | ||
ARCELLX | 86,80 | -1,84 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
APOGEE THERAPEUTICS | 52,45 | -1,43 % | Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million | SAN FRANCISCO and BOSTON, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 49,740 | -2,03 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 21,320 | -5,87 % | UBS bestätigt Kaufempfehlung für Summit Therapeutics vor ESMO-Daten | ||
COGENT BIOSCIENCES | 16,250 | +0,37 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WALTHAM, Mass. and BOULDER, Colo., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
BICARA THERAPEUTICS | 17,780 | -2,58 % | Bicara Therapeutics Inc.: Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | Updated data from Phase 1/1b trial presented at 2025 ASCO Annual Meeting demonstrated deep and durable responses in 1L HPV-negative R/M HNSCC Data from additional Phase 1/1b expansion cohorts evaluating... ► Artikel lesen |